OncoImmunology

期刊名

OncoImmunology

ONCOIMMUNOLOGY

ISSN / eISSN

2162-4011 / 2162-402X

目标和范围

Tumor immunology deals with the natural or therapy-induced recognition of cancers, as well as with the intricate interplay between oncogenesis, inflammation and immunosurveillance. We now create a new, high-profile journal, OncoImmunology, that specifically deals with tumor immunology. Recent progress has allowed for the first clinical demonstration (and FDA approval) of anticancer immunotherapies. There is also an ever growing suspicion that - unexpectedly - many of the currently used chemotherapeutic agents depend in their efficacy on the active contribution of immune effectors. To use a drastic metaphor, oncologists who applied successful chemotherapeutic (or radiotherapeutic) regimens have taken advantage of the immune system's capacity to recognize tumor-specific or tumor-associated antigens and to control cancer (stem) cell growth, without being aware of the invisible helping hands. As a result, immunological biomarkers are becoming ever more important to determine the prognosis of cancers and to predict the efficacy of chemotherapies. There is also a strong rationale in favor of combining conventional anticancer therapies with immunotherapies.
OncoImmunology will accept high-profile submissions in the fundamental, translational and clinical areas of tumor immunology. Submissions dealing with solid or hematological cancers, inflammation, innate and acquired immune responses will be welcome.

研究方向

免疫学

肿瘤学

CiteScore

12.50 查看趋势图

CiteScore 学科排名

类别	分区	排名
Medicine - Oncology	Q1	#37/366
Medicine - Immunology and Allergy	Q1	#27/211
Medicine - Immunology	Q1	#31/217

Web of Science 核心合集

Science Citation Index Expanded (SCIE)	Social Sciences Citation Index (SSCI)
Indexed	-

类别 (Journal Citation Reports 2023)	分区
IMMUNOLOGY - SCIE	Q1
ONCOLOGY - SCIE	Q1

H-index

49

出版国家或地区

UNITED STATES

出版商

Landes Bioscience

年文章数

174

Open Access

NO

通讯方式

530 WALNUT STREET, STE 850, PHILADELPHIA, USA, PA, 19106